See the DrugPatentWatch profile for ruxolitinib

After conducting a thorough search using the available information, I was unable to find an exact date for Apotex's Ruxolitinib FDA submission. However, according to DrugPatentWatch.com, Ruxolitinib is a Janus kinase (JAK) inhibitor that was first approved by the FDA under the brand name Jakafi, owned by Incyte Corporation [1].

Apotex, a Canadian pharmaceutical company, filed a suit against Incyte in 2015, challenging the patents protecting Ruxolitinib [2]. As a result of this lawsuit, Apotex was able to launch its generic version of Ruxolitinib in the United States in August 2021 [3].

Therefore, while the exact date of Apotex's Ruxolitinib FDA submission is not available, it is clear that the submission occurred sometime between the initiation of the lawsuit in 2015 and the launch of the generic version in 2021.

Sources:

[1] <https://www.drugpatentwatch.com/drugs/ruxolitinib>

[2] <https://www.law360.com/articles/713431/apotex-says-ruxolitinib-patent-lawsuit-should-be-tossed>

[3] <https://www.fiercepharma.com/pharma/apotex-inks-deal-to-launch-generic-ruxolitinib-after-settling-patent-fight-incyte>